LivaNova initiates targeted commercial launch of Essenz patient monitor

An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe

LivaNova announced the receipt of regulatory approvals and the start of a targeted market commercial launch for the Essenz Patient Monitor. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures. Having recently received U.S. Food and Drug Administration 510(k) clearance and CE Mark, LivaNova initially launched the Essenz Patient Monitor in the U.S. and Europe in hospitals that were involved in its user-centric design and development program. Additionally, the patient monitor provides important decision-making support for the perfusionist during the entire CPB procedure, is compatible with the LivaNova S5 heart-lung machine and will be a key feature of the complete Essenz Perfusion System, which encompasses a next-generation heart-lung machine. The Essenz Perfusion System is currently under development and is expected to launch in stages later this year beginning with limited commercial launches.

“The Essenz Patient Monitor provides advanced and insightful data through one central screen and supports us in making data-driven decisions throughout a case,” said Ed Overdevest, Clinical Perfusionist, Heartbeat, Catharina Hospital, Eindhoven, The Netherlands, which was the first location to adopt the patient monitor for clinical use. “With the monitor, we can individualize the patient management strategy using features such as the intra-operative quality indicator threshold and goal-directed perfusion modules. The combination of insightful data with an intuitive interface enabled our team to implement it for clinical use in the operating room almost immediately.”

The Essenz Patient Monitor is the result of extensive consultation with perfusionists and is based on 30 years of LivaNova experience informing clinical outcomes using patient data and establishing goal-directed perfusion (GDP) as the standard of care. GDP is a set of parameters monitored during CPB to optimize perfusion, aiming to reduce mortality risk and minimize postoperative complications.